|
The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: ---------- Tissue Regenix Group PLC - Leeds, England-based regenerative medical devices firm - Requests the temporary suspension of trading on AIM of the company’s shares with immediate effect. This will allow the new senior leadership team to further consider the previously announced restatement of revenue for the financial year to December 2024, the impact this has on first half adjusted earnings before interest, tax, depreciation and amortisation, and the cash-position and ongoing expected performance of the business. Until this further review takes place the company is not in a position to clarify its financial position, Tissue Regenix says. Strict financial controls are being implemented, and a comprehensive review of the cost structure is already underway, targeting a $2 million plus cost reduction. The board remains ‘committed to ensuring the recovery of the business and delivering sustainable, long-term earnings growth for shareholders.’ ---------- Eco Buildings Group PLC - London-based modular construction business - Clarifies that the initial deposit of €12.8 million from the Chilean government’s flagship housing programme relates to the construction of 1,214 homes, not 607 homes as previously stated on Tuesday. The revised figure reflects a variation from the original contract to accelerate the schedule of delivery in year one. All other information from Tuesday’s statement remains unchanged, including the overall contract value of €420 million and the total programme of 20,000 homes over seven years. ---------- Burford Capital Ltd- London- and New York-based litigation finance provider - Provides an update on the status and expected timeline of litigation involving Argentine energy company YPF in the US and foreign courts. Explains the main appeal is scheduled for oral argument before a three-judge panel of the Second Circuit on October 29. Stresses that the US government has not taken any position or made any filing with respect to the appeal. After oral argument, the Second Circuit panel will deliberate and write an opinion in the case, although there is no deadline or convention about the timing for the release of that opinion and its accompanying judgement. Once the Second Circuit issues its opinion and judgement, a party dissatisfied with the outcome can seek rehearing. Also notes, Argentina ‘routinely attempts to delay court proceedings, and although those efforts are not always successful.’ ---------- Mosman Oil and Gas Ltd - Sydney-based mining company targets helium, hydrogen and hydrocarbons in the US and Australia - Raises £500,000 through a fully subscribed retail offer at 0.0225 pence per share. Together with the £1.7 million placing, Mosman has now raised a total of£2.2 million. Executive Chair Carl Dumbrell says the financing leaves ‘Mosman well financed to advance our world-class helium portfolio in Colorado.’ ‘We now look to a period of significant news flow including the forthcoming 3D seismic and extended well test programmes at Sagebrush, as well as continued development activity at Coyote Wash. With strong cash backing and two high-quality helium assets, Mosman is in a great position to deliver meaningful development milestones through the coming months,’ he adds. ---------- Oxford BioDynamics PLC - Oxford, England-based biotechnology company - Raises £7 million through a placing and subscription at £0.003 each, representing around 54% of the enlarged share capital. The funds will provide working capital as sales of its EpiSwitch-based PSE prostate cancer test continue to rise and the firm pursues new out-licensing and distribution deals. A general meeting will be held on November 7 to approve the share issue. Executive Chair Iain Ross says: ‘Whilst our PSE Test sales continue to grow month on month, our new partnership with Google Cloud is progressing and third party partnership discussions are ongoing, these funds will help us to execute our plans to create increasing value for our shareholders.’ ---------- Genflow Biosciences PLC - London-based biotechnology firm - Announces that its second European patent application has been published in the European Patent Bulletin. Publication of the patent application in the European Patent Bulletin follows entry into the European phase under the Patent Cooperation Treaty and represents a key milestone in Genflow’s expanding intellectual property portfolio. Chief Executive Eric Leire says: ‘The publication of our second European patent marks another important validation of our science and IP strategy.’ ---------- Trellus Health PLC - London-based healthcare company - Signs a 12 month contract with one of the ‘largest global clinical research organisations’ to support recruitment and enrolment optimisation for an ongoing mid-stage clinical trial in the field of immunology and inflammation. The contract is due to commence later this year. The clinical trials sector remains a strategic growth area for the group and as a result it launches Trellus TrialSet. This program is designed to support potential clinical trial participants by identifying individuals with low resilience, who may be hesitant to enrol in the trial, and provide structured services to strengthen their readiness. This is expected to enhance recruitment efficiency, improve retention, and deliver cost savings for partners. ---------- Accsys Technologies PLC - London-based wood building products manufacturer - Agrees €55 million new debt financing facilities provided on an equal basis by ABN AMRO Bank NV and HSBC UK Bank PLC. The facilities comprise a €20 million term loan and a €35 million revolving credit facility and are committed for a three-year term, maturing in October 2028. The facilities include an option to extend for a further year. The refinancing replaces the current ABN AMRO facility, provides additional liquidity for the group and strengthens the group’s financial position on improved financial terms. ---------- Polarean Imaging PLC - medical imaging technology company - Says its board has launched a strategic review of the firm’s direction and structure amid a ‘highly challenging’ UK small-cap market for MedTech stocks. Polarean says it is assessing options to maximise shareholder value, including cost reductions and potentially cancelling its AIM listing to transition to a private company structure. The firm says no decision has been made and any delisting would require shareholder approval. Polarean adds it remains focused on advancing its Xenon MRI technology and commercial growth during the review. ---------- Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
